Влияние на кровообращение
Количественная ЭКГ, фазовый анализ левого желудочка, артериальное давление, центральная и церебральная гемодинамика — инструментальная документация кардиоваскулярных реакций на гирудотерапию
Instrumental Evidence Profile
International Clinical Evidence
The cardiovascular effects of hirudotherapy bridge mechanistic pharmacology to clinical outcomes through objective instrumental documentation. Unlike subjective symptom assessment, the data presented here derive from electrocardiographic area calculations (validated against the gold standard of coronary angiography), polycardiographic phase timing, calibrated sphygmomanometry, echocardiographic volume measurements, and rheoencephalographic impedance analysis. The following sections demonstrate that hirudotherapy produces measurable, statistically significant improvements in cardiac electrical activity, myocardial contractile function, arterial blood pressure, and both central and cerebral hemodynamics.
Key finding across all modalities: Hirudotherapy operates as a corrective intervention — it corrects abnormal parameters without displacing normal values. Elevated blood pressure decreases; normal blood pressure is unchanged. Hyperkinetic cardiac output decreases; hypokinetic cardiac output increases. This bidirectional correction distinguishes hirudotherapy from unidirectional pharmacologic agents and is consistent with the corrective hemostatic model established for coagulation parameters.
Last updated: March 14, 2026
Количественная планиметрическая ЭКГ — методология
Standard qualitative ECG analysis is universally used in CAD diagnosis. The quantitative planimetric method — developed by Stamboltsyan and Mikhaelyani (1967) — extends diagnostic capability by measuring the actual area of ventricular complex components. The technique involves fivefold photographic enlargement of the ECG complex onto graph paper, with direct cell counting to calculate areas in mm². After reduction by a factor of 25, the true area is obtained.
Method Details
- Area convention: Positive (+) if waveform lies above the isoelectric line; negative (−) if below. Biphasic T waves are summed algebraically
- Portions measured: Initial (QRS complex) and terminal (ST segment + T wave) calculated separately
- Precordial averaging: Mean ST-T area = (V1+V2+V3+V4+V5+V6) ÷ 6. Right precordial = (V1+V2+V3) ÷ 3. Left precordial = (V4+V5+V6) ÷ 3
- Pathological threshold: Individual values compared to healthy subject reference ± 2 SD
- Tape speed: 50 mm/s for optimal complex resolution
Reference Values — 35 Healthy Subjects (Ages 35–60)
| Lead Group | Mean ST-T (mm²) | ± SD |
|---|---|---|
| Right precordial (V1–V3) | 13.2 | ± 4.536 |
| Left precordial (V4–V6) | 13.0 | ± 5.882 |
| All 6 precordial leads | 13.1 | ± 5.409 |
Isakhanyan (1991). Reference population: ages 35–60, no CAD.
The ST-T area serves as a sensitive "barometer" of myocardial perfusion, reflecting the smallest changes in coronary blood flow. Quantitative calculations detect trends toward increase or decrease in ST-T values that are not apparent from qualitative visual inspection alone. The value of this method has been demonstrated in diagnosing subclinical CAD manifestations (Isakhanian, 1976–1982), differentiating infectious-allergic myocarditis from CAD (Isakhanian, 1981), and monitoring therapeutic efficacy (Stamboltsyan et al., 1970).
Валидация относительно коронарной ангиографии — n = 32
Gelshtein & Isakhanyan (1984) — Quantitative ECG vs Selective Coronary Angiography
32 patients with angina pectoris undergoing CABG. Comparison of qualitative ECG, quantitative planimetric ECG, and selective coronary angiography (gold standard).
| Parameter | Qualitative ECG | Quantitative ECG | p |
|---|---|---|---|
| Diagnostic accuracy | 81.25 ± 7.17% | 96.87 ± 3.07% | <0.01 |
| False negatives | 6 patients | 1 patient | — |
| Localization accuracy | 28.12 ± 7.94% | 65.62 ± 8.31% | <0.01 |
The quantitative method permitted clarification of coronary disturbance localization in one-third of cases where qualitative analysis failed. Precordial leads showed greatest diagnostic sensitivity — fluctuations in ST-T areas were identified more frequently and with greater amplitude deviation from normal in precordial leads.
ЭКГ-ответ на однократный сеанс — n = 40 пациентов с ИБС
Protocol: 5–6 ML applied to the left anterolateral chest wall (precordial region). Triple control recordings obtained the preceding day (9:00, 11:00, 13:00) with all therapeutic interventions suspended to establish intraday variability baseline. Treatment day: baseline ECG → ML application → ECG immediately after detachment → 1.5 h → 3 h. All other therapies suspended during study period.
Quantitative ECG Parameter Changes — Single ML Application (Isakhanyan, 1991)
| ECG Area | Control (M ± m) | Immediately After | 1.5 h Later | 3 h Later |
|---|---|---|---|---|
| Mean ST-T, 6 precordial leads (mm²) | 15.47 ± 8.41 | 35.01 ± 8.49 (p<0.05) | 40.27 ± 8.39 (p<0.05) | 21.11 ± 4.26 (p>0.5) |
| Mean ST-T, left precordial (mm²) | −21.47 ± 5.72 | −16.73 ± 3.12 (p<0.05) | −7.02 ± 5.73 (p<0.05) | −21.71 ± 5.85 (p>0.1) |
2.6×
ST-T area increase
40/40
Positive response rate
~1.5 h
Peak effect time
Qualitative T-Wave Changes
Qualitative T-wave changes in V5 and V6 were present in all 40 patients at baseline. TV4 was normal in only 3 cases. At 1.5 h post-detachment, TV5 became positive in 4 patients. Observed transition patterns:
- Negative → biphasic → flat → positive
- Biphasic → flat or positive
- Small positive → larger positive
- ST-segment restoration in 5/10 patients with baseline deviation
Intraday Control Validation
Triple control recordings (9:00, 11:00, 13:00 the preceding day, all therapies suspended) showed only minor physiological fluctuations within normal range. This establishes that the 2.6-fold ST-T increase and left precordial improvement following hirudotherapy exceeded normal intraday variability and are attributable to the therapeutic intervention rather than spontaneous variation.
Interpretation: The positive quantitative ECG response signifies coronary vasodilation through a cutaneous-visceral reflex pathway. The therapeutic stimulus applied from the cardiac reflex zone (precordial area, corresponding to dermatomes C2–C5 and Th1–Th5) selectively dilates coronary vessels. The left precordial leads demonstrated greater sensitivity, consistent with the predominant localization of pathology in the anterolateral and apical walls.
ЭКГ-ответ на курс лечения — n = 18 пациентов с ИБС
Landmark Quantitative Finding
Quantitative ECG Dynamics During Treatment Course (Isakhanyan, 1991)
| ECG Area | Before Treatment | After 1st Session | After 2nd Session | After Course |
|---|---|---|---|---|
| Mean ST-T, 6 leads (mm²) | 21.71 ± 7.43 | 52.90 ± 8.46 (p<0.05) | 55.93 ± 8.57 (p<0.05) | 56.89 ± 8.78 (p<0.02) |
| Mean ST-T, left precordial (mm²) | −27.98 ± 5.27 | −14.97 ± 4.32 (p<0.05) | −10.07 ± 4.07 (p<0.05) | +4.23 ± 3.98 (p<0.001) |
The reversal from −27.98 to +4.23 mm² represents a transition from pathological to normal coronary perfusion. The six-lead mean showed progressive improvement: 21.71 → 52.90 → 55.93 → 56.89 mm², with the greatest gain after the first session and sustained improvement through the course.
Qualitative T-Wave Evolution During Course — 54 T Waves Tracked
In 18 patients, 54 T waves (3 precordial leads × 18 patients) were tracked across control and three treatment sessions:
- Pathological T waves in left precordial leads decreased progressively through sessions I, II, and III
- TV4: Negative in 10 patients at baseline → 5 after first session → 6 after course (with T-wave amplitude improvement in remaining)
- TV5: Negative in 11, small positive in 6 at baseline → after course: negative in 6, flat/weakly positive in 10
- ST-segment deviation: Present in 5/18 at baseline; fully or partially restored in 3 after course
- Transition pattern: Negative → biphasic → flat → positive (each step indicating improved coronary perfusion)
Qualitative analysis detected clinical improvement but did not provide the complete picture — the quantitative method revealed improvements in cases where T-wave polarity remained unchanged but amplitude shifted.
Оценка при остром инфаркте миокарда — n = 15
Individual Lead Analysis in Acute MI (Isakhanyan, 1991)
In the acute MI subgroup (n = 15), averaged precordial values were not used because the direction of ST-T deviations in precordial leads is frequently inconsistent depending on the location of the myocardial injury zone — areas of opposite sign cancel out and distort the picture. Instead, area curves were constructed for each precordial lead individually.
Results: The positive quantitative response to hirudotherapy manifested as a tendency toward restoration of the intermediate (RS-T interval) and terminal (T wave) portions of the ventricular complex. This indicates that hirudotherapy reduces the degree of both myocardial ischemia (T-wave restoration) and injury (ST-segment restoration). The pathological Q wave — indicating prior necrosis — was not expected to change with treatment.
Important Consideration
Фазовый анализ левого желудочка — поликардиографический метод
Prior to these studies, no published investigations had analyzed changes in myocardial contractile function during hirudotherapy. Phase analysis of left ventricular systole was performed using the polycardiographic (PCG) method: simultaneous recording of ECG (standard lead II), phonocardiogram from the cardiac apex, and sphygmogram from the carotid artery. Systolic phases measured: Q-first heart sound interval, isometric contraction phase, ejection phase, mechanical systole, electrical systole, and Karpman's intrasystolic index (ISI = ejection phase ÷ mechanical systole × 100%).
Reference Values — 25 Healthy Subjects (Isakhanyan, 1991)
| Phase | Range (s) | M | ± m |
|---|---|---|---|
| Q – first heart sound | 0.05 – 0.08 | 0.064 | 0.003 |
| Isometric contraction phase | 0.02 – 0.06 | 0.040 | 0.058 |
| Ejection phase | 0.24 – 0.30 | 0.265 | 0.011 |
| Mechanical systole | 0.25 – 0.36 | 0.327 | 0.005 |
| Electrical systole | 0.33 – 0.36 | 0.380 | 0.077 |
| E-M systole difference | 0.02 – 0.09 | 0.056 | 0.01 |
| Cardiac cycle (R–R) | 0.66 – 1.06 | 0.820 | 0.014 |
| Karpman's ISI (%) | 75.0 – 88.0 | 81.00 | 1.449 |
Single Session — n = 27
Contractile function impaired in 17/27 at baseline. After a single application of 5 ML to the precordial area:
- Restoration in 10 patients (37% immediate response rate)
- Q-first heart sound: prolonged in 5 → 3 at 1.5 h
- Isometric contraction: pathological in 7 → 3 at 3 h
- Ejection phase: deviated in 12 → restored in 4
- Karpman's ISI: restored in 6 patients
Peak improvement at ~1.5 h, paralleling ECG improvement kinetics.
Treatment Course — n = 15
Baseline impairment in 9/15. Three sessions, average 5 ML per session to precordial area:
- Ejection phase: restored in 6/6 (100% of those with baseline abnormality)
- Isometric contraction: restored in 2 patients
- Overall improvement in 5 patients
- Worsening in 1 patient (slight deviation in isometric contraction phase and Karpman's ISI)
- Unchanged in 3 patients (impaired before and after)
The complete ejection phase restoration rate (6/6) is notable, though subgroups were too small for formal statistical analysis.
Артериальное давление — данные по >1 200 пациентам
Treatment of hypertension with leeches has been practiced since the mid-20th century (Bottenberg, 1935–1983; Zaslavskaya, 1940; Lukashev, 1948; Galkin, 1956; Dotsenko, 1956). Interest has resurged with modern controlled studies. The evidence base encompasses more than 1,200 patients across five major studies.
Blood Pressure Studies — Comprehensive Evidence
| Study | Year | n | Design | Key Finding | Level |
|---|---|---|---|---|---|
| Yena | 1998 | 46 | Prospective | SBP −57.8, DBP −26.0 mmHg. Sustained at 4 months (p<0.05) | III |
| Sidorov, Gileva et al. | 2003 | 141 | Controlled | 61.9% significant BP decrease; 28.6% transient elevation; controls: no change | IIb |
| Sekretova & Kulagin | 2003 | 1,020 | Large case series | HT as leading treatment for stage III HTN with arrhythmia + CHF. No initial elevation | III |
| Kamenev et al. | 2001 | NR | Prospective | SBP 136.6→126.1 (p<0.05); DBP 88.3→75.1 (p<0.05) | III |
| Isakhanyan | 1991 | 47 | Two-group comparison | Hypertensive: SBP ↓ p<0.05. Normal BP: unchanged — corrective model | III |
Key Finding: Corrective Model
Прекордиальная vs печёночная аппликация — два различных механизма
Precordial Route — Neural Vasodilation
Mechanism: Reflex (cutaneous-visceral) pathway. Therapeutic stimulus applied from the cardiac reflex zone (precordial area, dermatomes C2–C5 and Th1–Th5) selectively dilates coronary and peripheral vessels.
- n = 18 (CAD + hypertension)
- SBP reduction significant at 1.5 h (p<0.05)
- DBP reduction: not statistically significant
- Primary target: coronary perfusion improvement
- Sustained systolic effect, limited diastolic response
A prolonged, substantial BP reduction should not be expected when ML are applied outside the reflex zone for hypertension (the mastoid process area).
Hepatic Route — Volume Reduction
Mechanism: Prolonged bleeding + bloodletting + reflex effect on the liver → improved hepatic circulation → decreased venous congestion and edema → reduced circulating blood volume → increased blood flow velocity → systemic circulation unloading.
| BP | Before | After | p |
|---|---|---|---|
| SBP (mmHg) | 172.00 ± 8.54 | 144.17 ± 5.67 | <0.02 |
| DBP (mmHg) | 98.33 ± 4.07 | 80.83 ± 2.32 | <0.001 |
n = 12 patients with hypertension + CHF I–III. 5–6 ML to right hypochondrium, 3 sessions, 4–5 day intervals. Liver size reduced by ≥1 cm during treatment itself (within 60–90 min).
Clinical implication: The two mechanisms are complementary. Precordial application acts primarily through neural vasodilation; hepatic application through volume reduction and hemodynamic unloading. The hepatic route produces more robust reductions in both SBP and DBP, particularly in patients with congestive heart failure where volume overload is the predominant pathophysiological driver. The primary reflex zone for arterial hypertension is the mastoid process area (Galkin, 1956; Dotsenko, 1956; Starodubskaya, 1998; Deryabin et al., 1999).
Application Sites for Hypertension — Site-Dependent Efficacy
| Site | Primary Mechanism | References |
|---|---|---|
| Mastoid processes (primary) | Neural reflex antihypertensive | Galkin 1956, Dotsenko 1956, Starodubskaya 1998, Deryabin 1999 |
| Hepatic (right hypochondrium) | Volume reduction, systemic unloading | Isakhanyan 1991, Skopichenko 1966 |
| Precordial area | Coronary vasodilation (limited BP effect) | Isakhanyan 1991 |
| Periauricular area | Neural reflex (alternative) | Zhuravsky et al. 1997 |
| Temporal area | Neural reflex (alternative) | Bardasarova 1970, Bondareva 1998 |
| Collar zone | Neural reflex (alternative) | Zadorova 1998 |
When ML are applied outside the mastoid processes, BP does not decrease in all patients and the reduction is of short duration (Galkin, 1956; Skopichenko, 1966; Bardasarova, 1973). This site-dependence supports the reflex mechanism.
Transient Hypertensive Response — Controversy & Evidence
Reports of Transient Elevation
Several authors reported at the VIII Conference of the Association of Hirudologists (November 2003, Moscow) that a slight or moderate rise in blood pressure was often observed immediately after ML application. The antihypertensive effect occurred after 30–60+ minutes.
Maksyutkina & Chekulaeva (2003) cautioned that patients with high baseline BP and vascular predisposition to hypertensive crises may develop serious complications — proposing that high-value arterial hypertension with crisis-prone course represents a relative contraindication.
Controlled Data Resolution
Methodological concerns: The cautionary reports had small samples, absent control groups, methods limited to BP measurement alone, no statistical analysis, and hypertension was not classified by etiology.
Higher-quality evidence: Sidorov et al. (2003; n=100+41 controls) demonstrated transient elevation in only 28.6% of patients (SBP +7.3%, DBP +4.9%). The Sekretova & Kulagin series (n=1,020) did not document initial BP elevation. The balance of evidence suggests the transient response is a minority phenomenon that does not negate the overall antihypertensive effect.
Comparison with venipuncture bloodletting: Both Lukashev (1948) and Ustinova (1969) documented that hirudotherapy lowers blood pressure for a longer period than conventional venipuncture bloodletting. This distinction may reflect the sustained pharmacologic action of SGS components — particularly the vasodilatory histamine-like compound and prostacyclin analogs — extending the hemodynamic effect beyond the duration attributable to volume depletion alone.
Central Hemodynamics — Bidirectional Correction
Bidirectional Hemodynamic Correction
Hyperkinetic Variant (Gantimurova et al., 2001)
Baseline: Elevated cardiac output, normal or low peripheral resistance — BP elevation driven by increased stroke volume.
- SI: 72.23 ± 2.59 → 61.78 ± 3.23 mL/m² (p<0.02) — decreased toward normal
- CI: 4.97 ± 0.14 → 4.19 ± 0.3 L/min/m² (p<0.01) — decreased
- Specific peripheral resistance: tendency to increase (compensatory response maintaining tissue perfusion)
→ BP decreased via reduced cardiac output
Hypokinetic Variant (Gantimurova et al., 2001)
Baseline: Depressed cardiac output, elevated peripheral resistance — BP elevation driven by high afterload.
- SI: 32.75 ± 2.2 → 41.21 ± 2.3 mL/m² (p<0.02) — increased toward normal
- CI: 2.02 ± 0.08 → 2.42 ± 0.14 L/min/m² (p<0.02) — increased
- Elevated specific peripheral resistance: decreased significantly
- Pulse pressure: increased
→ BP decreased via reduced afterload + improved forward flow
Yena (1998) — n = 46 Hypertensive Patients
ML applied to mastoid processes. Significant increase (p<0.05) in cardiac stroke volume. Decrease (p<0.05) in the minute volume index. Reduction (p<0.05) in total peripheral vascular resistance (TPVR). These findings indicate a hemodynamic shift toward a more efficient cardiac output pattern with reduced afterload. At 4-month follow-up, BP remained significantly reduced from baseline: SBP 178 ± 9.0 mmHg, DBP 100 ± 7.0 mmHg (p<0.05).
Pharmacotherapy Control Group (Gantimurova et al., 2001)
In the control group (n=10, pharmacological treatment only), no significant hemodynamic changes were observed. The absence of comparable hemodynamic improvement with pharmacotherapy alone suggests that hirudotherapy provides additive benefit beyond standard drug therapy for central hemodynamic optimization.
Cerebral Hemodynamics — Rheoencephalography & Transcranial Doppler
Rheoencephalographic Improvements (Gantimurova et al., 2001)
After a course of HT in hypertensive patients (n=59 main group), all rheoencephalographic parameters improved significantly:
| Parameter | Right | Left | p |
|---|---|---|---|
| Rheographic index ↑ | +60% | +63.6% | <0.001 |
| Ascending limb time ↓ | −18.2% | −15.6% | <0.01 |
| Dicrotic index ↓ | −15.6% | −19.2% | <0.05–0.01 |
| Diastolic index ↓ | −15.0% | −19.8% | <0.05 |
Comparison group (pharmacotherapy only): only ascending limb time reduction (14.3%, p<0.05). By end of treatment, rheographic index was significantly higher and dicrotic/diastolic indices significantly lower in the HT group vs controls.
Echocardiographic & Doppler Findings (Kamenev et al., 2001)
Patients with impaired central and cerebral hemodynamics. ML application with serial echocardiography and transcranial Doppler:
| Parameter | Before | After | p |
|---|---|---|---|
| EF (%) | 52.9 ± 9.1 | 66.4 ± 11.9 | <0.05 |
| HR (bpm) | 67.2 ± 8.1 | 73.8 ± 13.2 | <0.05 |
| SBP (mmHg) | 136.6 ± 13.1 | 126.1 ± 16.1 | <0.05 |
| DBP (mmHg) | 88.3 ± 2.4 | 75.1 ± 17.3 | <0.05 |
The EF increase from 52.9% to 66.4% represents a shift from borderline reduced to normal systolic function. Cerebral assessment: increased peak systolic velocity in extracranial and intracranial arteries, increased total cerebral blood flow and cerebral blood flow fraction of minute volume. Improved cerebral perfusion was mediated primarily by blood flow redistribution and vasodilation rather than increased cardiac output.
Heart Rate & Rhythm — Observations
Heart Rate Response Pattern
No significant, consistent heart rate changes were directly attributable to hirudotherapy. Observed variations likely reflect multiple competing physiological influences: patient anxiety (tachycardia), hemodynamic effect of blood loss (reflex tachycardia), and reduced heart failure severity from circulatory decompression (reflex bradycardia).
- 55 CAD patients: Pre-existing tachycardia in 13 patients. After ML treatment course: pulse slowing in 7, acceleration in 1, persisted in 5. Predominance of slowing (54%) in tachycardic patients is consistent with reduced sympathetic drive from hemodynamic burden relief
- Confirmatory: Demin (1958a) noted pulse slowing after HT in patients with pre-existing tachycardia
- Notable case: Zadorova (1998) described paroxysmal atrial fibrillation converting to normosystolic form after the first HT session, with full restoration of sinus rhythm after the second treatment. Mechanism may involve improved atrial perfusion, reduced atrial stretch, or autonomic modulation through the reflex pathway
This single case report suggests potential antiarrhythmic effects meriting prospective investigation.
Six Mechanistic Pathways — Integration with SGS Pharmacology
The cardiovascular effects documented on this page are attributable to multiple SGS-mediated pathways operating simultaneously:
1. Coronary Vasodilation
Cutaneous-visceral reflex from the precordial reflex zone. Therapeutic stimulus at dermatomes C2–C5 and Th1–Th5 selectively dilates coronary vessels. Documented by quantitative ECG: 2.6-fold ST-T area increase.
2. Anticoagulant & Antiplatelet
Hirudin-mediated thrombin inhibition and antiplatelet activity improve microcirculatory blood flow. See Chapter 9 for coagulation parameter documentation (APTT, fibrinogen, platelet aggregation).
3. Histamine-Like Vasodilation
SGS contains a histamine-like vasodilatory compound that enhances local and regional blood flow beyond the reflex pathway. Contributes to sustained antihypertensive effect exceeding simple bloodletting.
4. Prostacyclin-Like Activity
6-keto-PgF1α (prostacyclin analog) in SGS contributes to vasodilation and platelet inhibition. Extends the hemodynamic effect duration beyond volume depletion alone (Lukashev 1948, Ustinova 1969).
5. Hyaluronidase Enhancement
Tissue permeability increase facilitates SGS distribution into surrounding tissues. Acts as a "spreading factor" that amplifies the reach of other bioactive components beyond the immediate bite site.
6. Venous Decompression
Bloodletting and hepatic drainage reduce preload and afterload. Particularly effective in CHF: liver size reduction by ≥1 cm within 60–90 minutes, decreased venous congestion, improved cardiac function.
Representative Case Reports
Patient K.V., Age 56
Diagnosis: Hypertensive disease stage II, CAD, stable exertional angina FC II, CHF.
Baseline: BP 180/95–170/100 mmHg. ECG: negative "coronary" T waves in V4–V6, biphasic TII, ST depression in left precordial leads.
Treatment: 3 HT sessions (5 leeches each, precordial area).
Result: BP 175/90 mmHg. T waves flattened in precordial leads. Clear increase in ST-T area in left precordial leads. Reduced frequency of anginal episodes with improved subjective condition.
Patient L.S., Age 57
Diagnosis: CAD, stable exertional angina FC III, post-infarction ischemic cardiomyopathy (posterior wall and apex).
Treatment: 3 HT sessions (7, 5, and 8 leeches respectively).
Result: Considerably improved well-being with less frequent and shorter anginal episodes. TV4: negative → positive. TV5: negative → flattened. Progressive increase in ST-T areas through the treatment course.
Confirmatory Evidence — Additional Reports
Independent Confirmations of ECG and BP Improvement
Multiple independent investigators have confirmed the cardiovascular effects documented by the primary studies:
- Demin (1958a), Aleshina (1959): ECG evidence of improved coronary circulation in CAD and hypertension after HT
- Zadorova (1998), Deryabin et al. (1999): ECG improvement in CAD and arterial hypertension
- Fedina & Korotygina (2001): Confirmed ECG-documented coronary circulation improvement
- Gubin & Gubina (2001): Serial Holter monitoring and paired bicycle ergometry in stable angina FC I–III — reduction or disappearance of ischemic manifestations after HT
Recommended Instrumental Monitoring
Monitoring Protocol for Cardiovascular Hirudotherapy
| Modality | When to Obtain | Parameters |
|---|---|---|
| 12-lead ECG | Baseline, post-session (0, 1.5, 3 h), after course | ST-T morphology, T-wave evolution, quantitative planimetric analysis if available |
| Blood pressure | Baseline, q15 min × 1 h post-session | SBP, DBP; note any transient elevation (occurs in ~29% per Sidorov) |
| Echocardiography | Baseline, after course (optional) | EF, stroke volume, cardiac index, wall motion |
| Transcranial Doppler | Baseline, after course (if cerebral indications) | Peak systolic velocity, cerebral blood flow fraction |
| 24-h Holter | Baseline, after course (if angina/arrhythmia) | Ischemic episodes, arrhythmia burden, ST changes |
Complete Evidence Table — All Circulatory Studies
| Study | Design | Population (n=) | Intervention | Key Outcome | Result |
|---|---|---|---|---|---|
| Isakhanyan 1991 | Prospective single-arm with intraday controls | CAD patients without acute MI (n=40) | 5–6 ML to precordial region, single session; ECG at 0, 1.5, 3 h | Quantitative planimetric ECG: mean ST-T area (6 precordial leads) | Mean ST-T area increased 2.6-fold (15.47→40.27 mm² at 1.5 h, p<0.05). Left precordial area improved from −21.47 to −7.02 mm² (p<0.05). Effect peaked at 1.5 h, returned to baseline by 3 h Triple intraday control recordings confirmed changes exceeded spontaneous variability |
| Isakhanyan 1991 | Prospective treatment course | CAD patients — treatment course assessment (n=18) | 3 sessions × 5 ML to precordial area, 3–5 day intervals | Quantitative ECG: mean ST-T area — serial course measurements | Left precordial ST-T reversed from −27.98 to +4.23 mm² (p<0.001). Six-lead mean increased from 21.71 to 56.89 mm² (p<0.02). Transition from pathological to normal coronary perfusion Most significant finding: reversal of pathological to normal values with cumulative treatment |
| Isakhanyan 1991 | Prospective assessment with individual lead analysis | Acute myocardial infarction patients (n=15) | ML to precordial area; individual precordial lead ECG analysis | Quantitative ECG: ST-T improvement tendency per individual lead | Tendency toward restoration of ST-T complex. Reduced degree of both myocardial ischemia and injury markers. Individual lead analysis required due to cancellation artifacts with averaged values Individual lead analysis essential in acute MI due to variable injury zone location |
| Gelshtein & Isakhanyan 1984 | Diagnostic validation study | Angina pectoris patients undergoing CABG (n=32) | Quantitative planimetric ECG vs selective coronary angiography | Diagnostic correspondence: qualitative vs quantitative ECG vs angiography | Qualitative ECG: 81.25% correlation with angiography (6 false negatives). Quantitative ECG: 96.87% (1 false negative, p<0.01). Localization accuracy: 28.12% qualitative vs 65.62% quantitative (p<0.01) Validated quantitative planimetric method as superior to qualitative ECG in CAD diagnosis |
| Isakhanyan 1991 | Prospective polycardiographic assessment | CAD patients — single session (n=27) | 5 ML to precordial area; polycardiographic phase analysis before and after | Left ventricular systolic phase restoration | Contractile function impaired in 17/27 at baseline. Restoration in 10 patients after single session. Isometric contraction: pathological in 7→3. Karpman ISI: restored in 6 patients. Peak improvement at 1.5 h First study of myocardial contractile function during hirudotherapy |
| Isakhanyan 1991 | Prospective treatment course | CAD patients — LV phase analysis course (n=15) | 3 sessions × 5 ML; serial polycardiographic assessment | LV systolic phase restoration over treatment course | Baseline impairment in 9/15. Ejection phase: restored in 6/6 (100% of those with baseline abnormality). Overall improvement in 5 patients. Worsening in 1 (isometric contraction phase deviation) Complete ejection phase restoration rate (6/6) notable |
| Yena 1998 | Prospective assessment | Hypertensive patients (n=46) | ML to mastoid processes; serial BP + hemodynamic monitoring at 4 months | Blood pressure, stroke volume, TPVR | SBP reduced by 57.8 mmHg, DBP by 26.0 mmHg (p<0.05). At 4 months: BP 178±9.0/100±7.0 (significantly reduced from baseline). Stroke volume increased (p<0.05), TPVR decreased (p<0.05) Combined BP + hemodynamic documentation; sustained effect at 4 months |
| Sidorov, Gileva et al. 2003 | Non-randomized controlled study | Hypertensive patients with pharmacotherapy controls (n=141) | HT (n=100) vs pharmacotherapy alone (n=41) | Blood pressure response pattern | Significant BP decrease in 61.9%. Transient elevation in 28.6% (SBP +7.3%, DBP +4.9%). Unchanged in 2 patients. Control group: no comparable hemodynamic changes Largest controlled hypertension study with HT. Documented transient elevation phenomenon |
| Sekretova & Kulagin 2003 | Large case series — retrospective analysis | Stage III hypertension with arrhythmias, CHF > stage I (n=1020) | HT as primary treatment (spa contraindicated population) | Blood pressure reduction, clinical improvement | HT described as leading treatment method for this population. No initial BP elevation documented in this series. Effective in patients where conventional spa treatment was contraindicated Largest single-center hypertension series in hirudotherapy literature (n=1,020) |
| Isakhanyan 1991 | Prospective two-group comparison | Group 1: CAD + hypertension (n=18); Group 2: CAD + normal BP (n=29) (n=47) | 5–6 ML to precordial area, 3 sessions | Blood pressure response by baseline BP status | Group 2 (normal BP): HT does not lower baseline normal BP levels. Group 1 (hypertension): SBP reduction significant at 1.5 h (p<0.05); DBP reduction not significant. Selective antihypertensive effect Key finding: HT lowers elevated BP but does NOT lower normal BP — corrective model |
| Isakhanyan 1991 | Prospective assessment | Hypertensive disease + cardiovascular disorders + CHF stage I–III (n=12) | 5–6 ML to right hypochondrium (hepatic area), 3 sessions, 4–5 day intervals | Blood pressure reduction via hepatic application | SBP: 172.00±8.54 → 144.17±5.67 mmHg (p<0.02). DBP: 98.33±4.07 → 80.83±2.32 mmHg (p<0.001). Liver size reduced by ≥1 cm during treatment. Superior DBP reduction vs precordial route Hepatic route: volume reduction mechanism. DBP reduction (p<0.001) exceeds precordial route |
| Kamenev et al. 2001 | Prospective echocardiographic + Doppler assessment | Patients with impaired central and cerebral hemodynamics (n=NR) | ML application; echo + transcranial Doppler pre/post-course | Ejection fraction, blood pressure, cerebral blood flow | EF: 52.9±9.1% → 66.4±11.9% (p<0.05). SBP: 136.6→126.1 (p<0.05). DBP: 88.3→75.1 (p<0.05). Increased peak systolic velocity in extracranial and intracranial arteries. Total cerebral blood flow increased EF improvement from borderline reduced to normal systolic function is clinically meaningful |
| Gantimurova et al. 2001 | Non-randomized controlled study | Arterial hypertension — hemodynamic variant analysis (n=79) | HT (n=59 main group) vs pharmacotherapy (n=10 control) + 10 additional | Central hemodynamics by baseline hemodynamic variant; cerebral indices | Hyperkinetic: SI 72.23→61.78 (p<0.02), CI 4.97→4.19 (p<0.01). Hypokinetic: SI 32.75→41.21 (p<0.02), CI 2.02→2.42 (p<0.02). Rheographic index +60% right, +63.6% left (p<0.001). Controls: no significant hemodynamic changes Bidirectional correction: HT reduces elevated output AND increases depressed output. Pharmacotherapy controls showed no comparable effect |
| Gubin & Gubina 2001 | Prospective with serial Holter and bicycle ergometry | Stable angina FC I–III (n=NR) | HT course; serial 24-h Holter monitoring + paired bicycle ergometry | Ischemic manifestations on Holter and exercise testing | Reduction or disappearance of ischemic manifestations after hirudotherapy course Confirmatory evidence using gold-standard ambulatory and exercise monitoring |
GRADE Evidence Level: Moderate
RCTs with limitations or strong observational studies
Evidence Summary — Key Quantitative Findings
| Domain | Key Finding | n | p-value |
|---|---|---|---|
| ECG single session | 2.6-fold mean ST-T area increase | 40 | <0.05 |
| ECG treatment course | Left precordial reversal: −27.98 → +4.23 mm² | 18 | <0.001 |
| Angiographic validation | 96.87% diagnostic accuracy (quant. ECG vs angiography) | 32 | <0.01 |
| LV contractility (single) | Return to baseline in 10/27 (37%) after single session | 27 | — |
| LV contractility (course) | Ejection phase: restored 6/6 (100%) | 15 | — |
| BP — hepatic route | SBP 172→144, DBP 98→81 mmHg | 12 | <0.001 |
| BP — controlled | 61.9% significant decrease (vs controls: no change) | 141 | sig |
| BP — largest series | HT as leading treatment, stage III HTN | 1,020 | — |
| Bidirectional correction | Hyperkinetic SI 72→62↓; Hypokinetic SI 33→41↑ | 79 | <0.02 |
| Ejection fraction | 52.9% → 66.4% (borderline → normal) | NR | <0.05 |
| Cerebral hemodynamics | Rheographic index +60–64% (vs controls: +14.3% only) | 69 | <0.001 |
| Corrective model | Elevated BP lowered; normal BP unchanged | 47 | <0.05 |
Evidence Gaps & Research Priorities
The instrumental evidence presented here represents the most comprehensive cardiovascular assessment of hirudotherapy in the published literature. However, several critical gaps remain:
- No randomized controlled trials (RCTs): All studies are prospective observational or non-randomized controlled. The Sidorov study (n=141) includes a control group but lacked randomization. Modern RCTs with standardized cardiovascular endpoints (MACE, hospitalization, mortality) are needed
- Modern instrumentation replication: Many studies used analog-era recording equipment (photographic ECG enlargement, mechanical polycardiographs). Digital ECG with automated ST-segment analysis, cardiac MRI, and 3D echocardiography would strengthen the evidence base and enable comparison with standard cardiovascular drug therapy outcomes
- Long-term follow-up: The Yena study (4-month data) is the longest follow-up. Cardiovascular outcomes require years of observation — studies with 1-year, 5-year, and 10-year follow-up are needed to establish whether the documented improvements translate into reduced cardiovascular events
- Dose-response relationships: The optimal number of leeches, sessions, and intervals have not been systematically studied. Most protocols used 5–6 leeches per session with 3–5 day intervals, but this was empirically derived rather than dose-optimization studied
- Mechanism attribution: The six mechanistic pathways operate simultaneously. Component-specific studies (e.g., isolated reflex stimulation vs SGS pharmacology vs volume depletion) would clarify mechanism contributions and enable targeted optimization
- Safety in acute MI: The potential for increased myocardial oxygen demand during HT-induced contractility improvement requires careful investigation with serial troponin monitoring and continuous telemetry before acute MI applications can be recommended
- Transient hypertensive response: The mechanism and clinical significance of the transient BP elevation reported in ~29% of patients (Sidorov et al.) needs prospective characterization — whether it predicts poor response, requires pre-treatment, or resolves spontaneously
ASH supports the development of randomized controlled trials with standardized cardiovascular endpoints (ECG, echocardiographic EF, ambulatory BP monitoring, MACE outcomes) to build upon the substantial instrumental evidence base and enable evidence-based integration with conventional cardiovascular therapy.
Связанные ресурсы
Cardiovascular Evidence
Clinical cardiology data: IHD, MI, hypertension, arrhythmias.
Подробнее →
Hemostasis & Coagulation
Anticoagulant mechanisms and coagulation parameter documentation.
Подробнее →
Cardiology
Clinical specialty overview — cardiovascular hirudotherapy.
Подробнее →
Atherosclerosis Mechanisms
Lipid-lowering, endothelial protection, and anti-aggregation science.
Подробнее →